AstraZeneca study shows benefits of new class of diabetes drugs

AstraZeneca has announced the results of a new study highlighting the benefits offered by SGLT-2 inhibitors (SGLT-2i), a newer class of diabetes medicines.

Results from the first large real-world evidence study of its kind showed that the risk of hospitalisation for heart failure and death from any cause in patients with type 2 diabetes was lower when using SGLT-2i therapies.

More than 300,000 patients across six countries were involved in the CVD-REAL study, which indicated that SGLT-2i therapies such as dapagliflozin, canagliflozin and empagliflozin reduced the rate of hospitalisation for heart failure by 39 percent and death from any cause by 51 percent compared to other type 2 diabetes medicines.

This is an important finding, as people with type 2 diabetes are two to three times more likely to experience heart failure and are at an increased risk of having a heart attack or stroke. Around 50 percent of deaths in these patients are caused by cardiovascular disease.

Dr Bruce Cooper, vice-president and head of global medical affairs at AstraZeneca, said: "CVD-REAL is the first study to observe these effects of SGLT-2i treatment in a much broader and lower-risk group of type 2 diabetes patients than previously evaluated in clinical trials."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.